Hemogenyx Pharmaceuticals Updates Share Capital and Voting Rights Structure

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an announcement.

Hemogenyx Pharmaceuticals plc, a clinical-stage biopharmaceutical group listed on the LSE and focused on therapies for blood and autoimmune diseases, operates from London with U.S. subsidiaries in New York City supporting its pipeline of product candidates and platform technologies. The company reported that as of 27 February 2026, its issued share capital comprises 6,425,429 ordinary shares with no treasury shares, establishing the same figure as the total number of voting rights for regulatory disclosure calculations under the FCA’s transparency rules.

This clarification of the company’s voting rights provides investors and other stakeholders with an updated denominator for assessing and reporting their holdings or changes in ownership. The announcement helps ensure compliance with U.K. market disclosure requirements and offers greater transparency regarding Hemogenyx Pharmaceuticals’ capital structure at the current stage of its development.

The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Spark’s Take on GB:HEMO Stock

According to Spark, TipRanks’ AI Analyst, GB:HEMO is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.

To see Spark’s full report on GB:HEMO stock, click here.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals plc is a London-headquartered, clinical-stage biopharmaceutical group listed on the LSE and focused on developing new medicines and treatments for blood and autoimmune diseases. The company operates U.S. subsidiaries in New York City and is advancing several complementary product candidates and platform technologies aimed at driving novel therapeutic development.

Average Trading Volume: 40,593

Technical Sentiment Signal: Strong Buy

Current Market Cap: £72.67M

Learn more about HEMO stock on TipRanks’ Stock Analysis page.